Similar findings were identified in Ethiopia37 and Mexico.38 In the literature, the practice of Self-Monitoring of Blood Glucose (SMBG) is promoted in patients with type 1 diabetes and in patients with insulin-treated type 2 diabetes.39,40 However, for patients with type 2 diabetes, SMBG seems to lead to slightly better glycaemic control only in the short term (less than 1 year).39 Therefore, the provision of personal glucometers to patients with type 2 diabetes, for SMBG, in the public healthcare sector, will have debatable long-term benefits in terms of glycaemic control. The gene discussed is INS; the disease is type 1 diabetes mellitus.